Foreground Capital

Millie is a maternity care platform and clinic that aims to improve clinical outcomes and provide a seamless experience for expectant and new parents, built by mothers and providers with firsthand experience, offering a new type of maternity clinic that supports remote health monitoring, home postpartum visits, and parenthood guidance through an app, including one-to-one doula coaching, and combining clinical care with practical support during and after the maternal phase to simplify access to care and enhance the overall experience for families.

Gesynta Pharma is a clinical-stage pharmaceutical company developing compounds that inhibit the pro-inflammatory enzyme mPGES-1. Its lead drug candidate, vipoglanstat (GS-248), is in development for endometriosis, a prevalent chronic inflammatory disease affecting women's health. Gesynta Pharma also has another drug candidate, GS-073, ready to enter clinical phase I trials.